Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Mastocytosis 4Recurrence 2Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mastocytosis, Systemic 2Gastrointestinal Stromal Tumors 2Blushing 2Ovarian Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-intestinal Stromal Tumours 1Gastro-Intestinal Stromal Tumour 1Gastro Intestinal Stromal Tumor 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

aflibercept 6Oxaliplatin 3Leucovorin 3Irinotecan 3Fluorouracil 2Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1raltitrexed 1monoclonal antibody YYB-101 1masitinib 1atezolizumab 1Vemurafenib 1Panitumumab 1Nivolumab 1IFL protocol 1HMPL-013 1Ethiodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Cancer Metastatic × masitinib × Clear all
NCT03556956 2020-12-08

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

AB Science

Phase 2/3 Completed
219 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡